The t(X;18)(p11.2;q11.2) translocation found in synovial sarcomas results in the fusion of the SYT gene on chromosome 18 to either of two closely related genes SSX1 and SSX2 on chromosome X. The resulting chimaeric genes express SYT-SSX1 or SYT-SSX2 fusion proteins in which the C-terminal amino acids of SYT are replaced by amino acids from the C-terminus of the SSX proteins. Using green fluorescent protein fusions we demonstrate that the SYT, SSX and the SYT-SSX proteins are nuclear proteins.We demonstrate that whilst the SSX1 protein has a uniform nuclear distribution the SYT protein has a speckled distribution in the cell nucleus, and this distribution is retained with the SYT-SSX2 fusion protein. Since the SYT speckles do not co-localise with PML-containing bodies (PODs) or spliceosomes it is possible that they represent a novel nuclear structure. Transfection of constructs expressing GAL4 fusion proteins demonstrate that the SYT domains present in the SYT-SSX fusion proteins can activate transcription of a luciferase reporter. It is proposed that the t(X;18) translocation results in the generation of an SYT-SSX transcriptional co-activator in which the addition of the C-terminal SSX domain to SYT provides a new interacting domain that redirects the SYT activation domain to different target promoters.
INTRODUCTION
Synovial sarcoma accounts for ∼10% of soft tissue tumours, frequently arising in the limbs adjacent to joints and tendons (1) . Cytogenetic analysis of synovial sarcomas has demonstrated the frequent presence of a characteristic chromosomal translocation, t(X;18)(p11.2;q11.2) (2-10). We have previously demonstrated that the t(X;18) results in the fusion of the SYT gene located on chromosome 18 to either of two genes designated SSX1 and SSX2, both located at Xp11.2 and encoding proteins with very similar amino acid sequences (11, 12) . The resulting chimaeric genes are transcribed to form 5′-SYT-SSX-3′ hybrid transcripts that are in turn translated to form SYT-SSX1 or SYT-SSX2 fusion proteins in which the C-terminal 8 amino acids of SYT are replaced by 78 amino acids from the C-terminus of either of the SSX proteins. Both the normal SYT protein and the C-terminal SSX regions present in the SYT-SSX fusion products failed to exhibit homology to known protein sequences (11) (12) (13) . However, the N-terminal half of both the normal SSX proteins (which are not retained in the fusion proteins) have a KRAB domain (12) which has previously been described in a number of transcription repressors containing zinc finger DNA-binding domains (14) . Since the SSX proteins do not have recognisable DNA-binding motifs it is likely that they act as co-repressors by association with as yet unknown sequence specific DNA-binding proteins. Also since the SSX1 and SSX2 proteins have very similar amino acid sequences throughout the two proteins (76% overall identity, 83% similarity) it is likely that they have similar functions.
The normal SYT gene is expressed in a wide variety of cell types during embryogenesis (15) and in the adult (11) , but the function of the protein is not known. However, the protein is rich in proline, glutamine and glycine, resembling the domains of a number of transcriptional activators (reviewed in 16). In addition, studies on other translocations demonstrate that the affected genes often encode transcription factors (reviewed in 17). It has therefore been postulated that the SYT gene may encode a transcription factor (11) . In order to gain some insight into the function of the SYT protein, the cellular localization of the protein was investigated using protein tagged with green-fluorescent protein (GFP). Also, since it seemed likely that the protein might be involved in controlling gene transcription, the protein was investigated for its ability to activate transcription in transfection experiments. The results demonstrated that SYT localises to discrete structures in the cell nucleus and that it has transcriptional activating properties. Furthermore these properties are retained in the SYT-SSX fusion protein.
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RESULTS

Cellular localisation of the SYT, SSX and the SYT-SSX proteins
The SYT protein was expressed as a fusion with the green fluorescent protein (GFP) in transient transfected cells and its cellular localisation determined by fluorescent microscopy, a technique that has been successfully used to localise a number of nuclear proteins, e.g., the PML nuclear protein to PODs (18) , nucleosporin (19) , cyclins (20) and hormone receptors (18, 21) . Figure 1A shows that GFP-SYT expressed in transfected NIH3T3 cells gives a green speckled pattern of fluorescence in the nucleus together with a faint fluorescence distributed throughout the nucleus. Figure 1B confirms that the fluorescence of GST-SYT is nuclear by co-staining the cell with the DNA interchelator DAPI (blue fluorescence). This speckled distribution contrasts with that seen with the GFP-SSX1 protein which, like most transcription factors, gives a more diffuse nuclear distribution ( Fig. 2A) .
The speckled pattern of GFP-SYT fluorescence was seen with several different transfected cell lines including a synovial sarcoma cell line (STS255), fibrosarcoma (HT1080), Cos-7 kidney cells breast carcinoma (MRC-5) and myeloid leukaemia (HL60) cells (data not shown). Figure 2B shows that the synovial sarcoma SYT-SSX2 protein retains the properties of the SYT protein in that the GFP fusion protein exhibits the same speckled nuclear distribution.
The GFP-SYT protein does not co-localise with PML or with spliceosomes
The speckled fluorescence seen with the GFP-SYT protein suggests that the SYT may be a component of a specific nuclear body. In order to investigate the nature of the SYT bodies we determined whether SYT co-localises with two other characterised nuclear bodies, PML-containing bodies (PODs) and spliceosomes, using antibodies to nuclear protein components of these bodies. The PML gene product, involved in the t(15;17) translocation in promyelocytic leukaemia, localises in PODs, and antibodies to the protein show a characteristic nuclear speckled pattern in normal cells (22) . Similarly, spliceosomes involved in pre-mRNA splicing also exhibit a speckled nuclear appearance (23) which can be seen with an anti-SC35 antibody (a common component of spliceosomes).
Immunocytochemistry with these antibodies demonstrate that SYT does not co-localise with PML (Fig. 3A) or with SC-35 (Fig. 3B) , indicating that SYT forms independent novel nuclear bodies distinct from PODs or spliceosomes.
SYT and SYT-SSX have transcriptional activating properties
The above data demonstrating that the SYT fusion protein is localised in the cell nucleus suggests that the protein could in some way be involved in regulating gene transcription. To investigate this, plasmid constructs which express the Gal4 DNA-binding domain or the complete SYT protein fused to the Gal4 DNA-binding domain (Fig. 4) were transfected into NIH3T3 fibroblasts together with a luciferase reporter containing either the tk promoter and five upstream Gal4 binding sites (5UAS) or the tk promoter alone. In each experiment the luciferase activity obtained with each fusion construct transfected in duplicate was compared with that obtained with the construct expressing the Gal4 DNA-binding domain alone which does not activate the tk promoter. The fold activation or repression of the reporter promoter by each fusion protein was thus calculated.
The averaged results of 10 different transfection experiments with the Gal4-SYT show that the protein stimulates the 5UAS-tk promoter 70-fold (Fig. 4) . This activation was dependent on binding to the Gal4 binding sites upstream of the tk promoter since Gal4-SYT has little effect on the tk-promoter lacking these sites (Fig. 4) . A similar set of experiments carried out with a GAL4-SSX1 construct demonstrate that the SSX protein has repressing activity, as expected for a protein containing a KRAB domain. In the SYT-SSX fusion proteins the C-terminal eight amino acids of the 387 amino acid SYT protein are usually replaced by 76 C-terminal amino acids of SSX1 or SSX2 (which do not contain the KRAB domain) (11, 12) . In a variant translocation 52 amino acids of SYT are replaced (12) . GAL4 fusions of two regions of SYT that are retained in the SYT-SSX fusions were tested for their transactivation properties, the N-terminal 158 amino acids (SYT-A) and the region from amino acid 159 to 314 (SYT-E). Both these regions were found to contain transcriptional activation activities, though the N-terminal domain SYT-A appeared to be weaker than full-length SYT or SYT-E (Fig. 4) . Thus the results of these transfection experiments provide evidence that the SYT protein can act as a transcriptional activator and the activating domain, which may be bipartite, is located in the part of the SYT protein retained in the SYT-SSX fusions. To confirm that the SYT-SSX fusion does indeed transactivate, a Gal4-SYT-SSX2 expressing construct was transiently transfected into cells with the reporter. It was found that the Gal4-SYT-SSX2 protein reproducibly activated transcription of the promoter, although the activity was apparently somewhat lower than that obtained with the unrearranged SYT protein in parallel experiments (Fig. 4) . Whether this difference reflects a true difference in the activities of two proteins or is merely due to differences in the stabilities of the two proteins in transfection experiments remains to be examined.
DISCUSSION
The results of this paper demonstrate that the normal SYT protein localises to the cell nucleus, exhibiting a speckled nuclear distibution as well as a diffuse background nuclear distribution. A number of other nuclear proteins, including transcription factors, proteins involved in splicing and replication proteins have been described as localising to discrete structures in the cell nucleus but in most cases the function of these structures is not known (reviewed in 24). Examples of proteins associated with oncogenesis that have been found to be localised in nuclear bodies are the Wilms tumour supressor protein WT1 (25) and the PML protein (22) . In the case of WT1, a spliced variant has been shown to localise in nuclear granules thought to be storage or recycling sites for spliceosome components and this has led to the suggestion that the protein has dual functions as a transcription factor and a splicing factor but it has also been suggested that localisation in the spliceosome could be a mechanism for sequestration of the protein and its dimers in an inactive form (26) . The PML protein is normally a component of nuclear bodies termed PODs of unknown function, but when fused to the RAR transcription factor in acute promyelocytic leukaemia cells as a result of chromosomal translocation its localisation is altered to a micropunctate pattern (22) . SYT is not localised in spliceosomes or with the PML protein in POD bodies, but it remains to be seen whether the protein co-localises with other proteins that have been described as localising in discrete nuclear structures [e.g., BRCA1 (27) ], or whether the protein is a component of a novel nuclear structure. The SYT-SSX2 fusion protein expressed from the translocated genes in synovial sarcomas has the same speckled nuclear distribution as the SYT protein and it is therefore apparent that oncogenesis is not a result of redistribution of the SYT protein. It could be argued that it is the nuclear relocalisation of the SSX protein in the fusion that contributes to the transformation of the synovial cells. However, the SSX genes are probably not expressed at all in the normal cell counterpart of the synovial sarcoma cell since we have found no evidence of expression of the unrearranged SSX1 or -2 genes or of the reciprocal SSX-SYT translocated gene in synovial sarcoma cells. Thus it is not the alteration of one of the SSX gene(s) that may be important for the generation of the sarcoma but the addition of the 3′-end of the previously inactive SSX gene(s) to the transcriptionally active SYT and the consequent expression of an altered SYT protein.
The amino acid sequence of the SYT protein does not exhibit any strong homologies with other known proteins and has no obvious DNA-binding domain. However the protein is rich in proline, glutamine and glycine, resembling the domains of a number of transcriptional coactivators such as Brahma (28) and the proline-rich coactivator OBF-1 (29) . The data demonstrating that SYT has transcriptional activation properties therefore suggests that SYT may also be a coactivator that binds to a sequence-specific DNA-binding protein. Thus the SYT protein may consist of two functional domains-an activation domain that interacts with the general transcription machinery and a domain for binding to a sequence-specific DNA-binding protein bound to promoters of as yet unknown target genes.
Similarly the SSX proteins, which contain a KRAB repression domain near the N-terminus, do not have a recognisable DNA-binding domain, and presumably also function through association with sequence-specific DNA-binding proteins through a second domain. We propose that this second domain resides in the C-terminal part of the SSX protein(s) that becomes fused to the SYT protein in synovial sarcomas. The consequence of this translocation would be that genes that are normally repressed by SSX will instead be activated by the SYT activation domain. If these target genes are involved in cell growth this would result in their upregulation and consequent transformation of the cell. In accordance with the model, the transfection data in Figure 4 indicate that the SYT activation domain residing in the N-terminal 314 amino acids of SYT is retained in the SYT-SSX2 protein. To confirm this model for the oncogenic mechanism of the SYT-SSX fusion protein it will be necessary to examine the effect of expressing the the SYT-SSX and the SYT proteins in transgenes and to identify the putative sequence-specific DNA-binding protein to which they bind. It will also be important to characterise the other components of the SYT bodies.
MATERIALS AND METHODS
Localisation of proteins tagged with GFP
The full-length open reading frames of SYT, SYT-SSX2, and SSX1 were cloned in-frame into the GFP expression vector pEGFPC1 (Clonetech). Each clone was sequenced using automated cycle sequencing. Cells for transient or stable transfection were cultured in DMEM, 10% fetal calf serum (Gibco-BRL) until 70% confluent. The exception was a synovial sarcoma cell line which was routinely cultured in HAMS F12, 20% fetal calf serum. Transfection was carried out using Lipofectamine (Gibco-BRL) following the manufacturer's instructions. Briefly ∼2 × 10 5 cells were seeded into 30 mm 6 well culture dishes. After 12 h the cells were washed with PBS and finally with DMEM minus fetal calf serum. A quantity of 2 µg of each expression plasmid was mixed with 100 µl of DMEM minus fetal calf serum. In a separate tube 10 µl of lipofectamine reagent was mixed with 90 µl of DMEM minus fetal calf serum. Each tube was incubated at room temperature for 1 h. The contents of the tubes were combined and incubated at the same temperature for a further 45 mins. The plasmid/Lipofectamine solution was diluted to 1 ml and incubated with the cells for 3 h. After this period the solution was tapped off and the cells washed with PBS and incubated with DMEM, 10% fetal calf serum (or HAMS F12 20% fetal calf serum in the case of the synovial sarcoma cell line). After 48 h the cells were trypsinised, washed and seeded onto culture slides (Nunc). After 12 h the slides were washed in PBS and fixed in fresh 4% paraformaldehyde for 20 min. The slides were mounted in PBS containing 0.1% DAPI and examined on a fluorescent microscope. Stable NIH 3T3 cell lines were created by an identical transfection method. Forty-eight hours after transfection cells were seeded into culture flasks containing the appropriate media plus 1 mg/ml G418 sulphate (Sigma) prepared in 10 mM HEPES buffer pH 7.5. G418 resistant colonies were selected after 4 weeks of culture in the selection media. The resistant colonies were examined for green fluorescence on slides prepared as described.
Immunocytochemistry
Cells expressing GFP fusion proteins either transiently or in a stable fashion were fixed as described above with 4% paraformaldehyde followed by PBS/1% Nonidet P40/20% sucrose when the SC35 antibody (Sigma) was used. Alternatively cells incubated with the PML antibody were first fixed with 100% methanol at -20_C for 5 min. Following fixation cells were incubated in blocking buffer (PBS/0.2% Tween/5% glycerol/1% BSA). Cells were incubated in this buffer with either a 1:200 dilution of an anti-human SC35 monoclonal antibody (Sigma) or a 1:100 dilution of an anti-human PML monoclonal antibody (Santa Cruz) for 1 h at room temperature. The cells were washed 3 times with PBS, 0.2% Tween and incubated in blocking buffer with a 1:35 dilution of anti-mouse Texas red conjugated second antibody (Sigma). Cells were washed 3 times in PBS/0.2% Tween and mounted in similar fashion. The slides were examined with a fluorescent microscope with the appropriate filters.
Transient transfection assay
The full-length cDNA encoding SYT was subcloned into the pMG147Spe vector downstream of, and in frame with the Gal4 DNA binding domain encoding region and the frame was verified by sequencing. The BamHI and EcoRV restriction sites, which interrupt the SYT cDNA at codons 158 and 314 respectively, were used to create the deleted constructs SYT-A (N-terminal BamHI fragment) and SYT-E (BamHI-EcoRV fragment). Gal4 constructs of SSX1 and the SYT-SSX2 fusion were made by PCR amplification and subsequent cloning of the full length cDNAs. The PCR products were downstream of, and in frame with the Gal4 DNA binding domain encoding region. The constructs were sequenced fully to verify the frame and that no PCR induced mutations had been incorporated. Two reporter constructs were used, both containing the luciferase gene under the control of an upstream tk promoter. One of the constructs also contained five Gal4 binding sites (5UAS) upstream of the promoter. NIH3T3 fibroblasts (2 × 10 5 ) were transfected with 2 µg reporter, 0.5 µg Gal4 construct and 0.5 µg CMV-β-galactosidase by the calcium phosphate precipitation method. Transfections were carried out overnight in six well plates, in DMEM containing 10% fetal calf serum. The cells were then refed and allowed to recover for ∼30 h. The cells were then serum starved overnight and refed for 8 h before harvesting. Cells were harvested and lysed using the Luciferase Assay System (Promega) according to the manufacturer's instructions. A β-galactosidase assay was performed on the cell lysate according to standard protocols. The lysate was measured for luciferase activity and the counts were nomalised against the β-galactosidase value to allow for the difference in transfection efficiency. The values obtained were expressed as fold activation over that observed with Gal4 alone, averaged from at least three independent experiments. All constructs were assayed in duplicate in each experiment and at least two independent plasmid preparations of the expressor and reporter constructs were assayed in different experiments. To normalise transfection efficiencies experiments were initially carried out by cotransfecting the CMV-β-galactosidase reporter but
